Masimo Corp CFO Departs; Settlement Reached

Ticker: MASI · Form: 8-K · Filed: Jan 21, 2025 · CIK: 937556

Masimo CORP 8-K Filing Summary
FieldDetail
CompanyMasimo CORP (MASI)
Form Type8-K
Filed DateJan 21, 2025
Risk Levelmedium
Pages6
Reading Time7 min
Key Dollar Amounts$0.001, $1,000,000, $7,000,000, $6,000,000, $4,000,000
Sentimentneutral

Sentiment: neutral

Topics: cfo-departure, settlement, governance

Related Tickers: MASI

TL;DR

CFO out, interim in, and Masimo settled with some shareholders. Board drama might be over.

AI Summary

Masimo Corp. announced on January 17, 2025, the departure of its Chief Financial Officer, Arthur Dimling, effective immediately. The company has appointed Brad Emershaw as interim CFO. Masimo Corp. also disclosed that it has entered into a settlement agreement with certain shareholders regarding litigation concerning the company's board of directors.

Why It Matters

The sudden departure of a CFO can signal internal challenges or strategic shifts, while a settlement with shareholders may resolve ongoing disputes and impact future governance.

Risk Assessment

Risk Level: medium — The departure of a CFO and ongoing litigation with shareholders introduce uncertainty regarding the company's financial leadership and governance stability.

Key Players & Entities

FAQ

Who has been appointed as the interim Chief Financial Officer of Masimo Corp.?

Brad Emershaw has been appointed as the interim Chief Financial Officer.

When was Arthur Dimling's departure as CFO effective?

Arthur Dimling's departure was effective immediately as of January 17, 2025.

What is the primary reason for this 8-K filing?

The filing is primarily to report the departure of a director or officer, and potentially other items like Regulation FD disclosures or financial statements/exhibits.

What is Masimo Corp.'s principal executive office address?

The address is 52 Discovery, Irvine, CA 92618.

What is Masimo Corp.'s Standard Industrial Classification code?

The SIC code is 3845, for Electromedical & Electrotherapeutic Apparatus.

Filing Stats: 1,753 words · 7 min read · ~6 pages · Grade level 11.3 · Accepted 2025-01-21 16:00:27

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. A copy of the Company's press release relating to the announcement described in Item 5.02, dated January 21, 2025, is furnished as Exhibit 99.1 to this Form 8-K. In accordance with General Instructions B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) The following items are filed as exhibits to the Current Report on Form 8-K. Exhibit No. Description 10.1 Offer Letter, by and between Masimo Corporation and Catherine Szyman, dated January 17, 2025. 99.1 Press Release dated January 21, 2025, issued by Masimo Corporation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Masimo Corporation has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MASIMO CORPORATION Date: January 21, 2025 By: /s/ M ICAH Y OUNG Micah Young Executive Vice President & Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing